Serán Bioscience Announces $200M Strategic Growth Transaction and Plans for New Commercial Facility

Serán Bioscience (“Serán” or “the Company”), a leading contract development and manufacturing organization (CDMO) providing a comprehensive suite of development, analytical and manufacturing services to pharmaceutical and biotechnology companies, announces a strategic growth transaction of more than $200 million. Bain Capital Life Sciences (“Bain Capital”) led the transaction, while existing investor Vivo Capital remains a key shareholder in the company. The partnership will support Serán’s continued growth with the build out of a new commercial-scale manufacturing facility.

Read the full article: Serán Bioscience Announces $200M Strategic Growth Transaction and Plans for New Commercial Facility //

Source: https://www.businesswire.com/news/home/20240917098677/en/Ser%C3%A1n-Bioscience-Announces-200-Million-Strategic-Growth-Transaction-and-Plans-for-New-Commercial-Facility

Scroll to Top